No Data
Lu Chongmao: The "1+" mechanism has approved a total of 5 new drug applications, with the cost of 2 drugs decreasing by nearly 30%.
Dr. Constance Chan, Director of Health, stated at the Legislative Council meeting today (8th) that since the new drug approval mechanism ("1+1" mechanism) took effect, the Department of Health has received inquiries from more than 80 pharmaceutical companies, totaling over 260, and has approved a total of 5 new drug applications. These include 2 treatments for metastatic colorectal cancer, 1 treatment for paroxysmal nocturnal hemoglobinuria, 2 treatments for patients with parathyroid cancer and a certain type of hypercalcemia in patients with primary hyperparathyroidism. Dr. Constance Chan revealed that two of the new drugs for the treatment of metastatic colorectal cancer have been included in the public hospital authority's list of specialty drugs. The public hospital authority has also successfully completed procurement discussions.
Hong Kong stocks have seen unusual movements, with CRO concept stocks generally under pressure. The emotions are influenced by the results of the USA election. Institutions point out that the probability of the Biosecurity Law being an independent law may
CRO concept stocks are generally under pressure. As of the time of publication, GenScript Biotech (01548) fell by 6.68% to HKD 10.9; Viva Biotech (01873) fell by 3.16% to HKD 0.92; Pharmaron (03759) fell by 2.64% to HKD 16.22.
3sbio (1530.HK): A domestic biopharmaceutical pioneer with abundant reserves of investigational products.
As a domestic biopharmaceutical pioneer, with stable growth of core products. 3sbio is a leading domestic biopharmaceutical company with rich experience in the research and development, production, and sales of biomedical products. The company currently has more than 30 listed products, including core products widely recognized globally.
Hong Kong stock concept tracking | The end of medical insurance negotiations is very encouraging for innovative drugs to be included in medical insurance at reasonable prices (with concept stocks)
The on-site negotiation and bidding stages for the adjustment of the national medical insurance pharmaceutical catalog in 2024 officially ended recently.
Is it the most 'rolled up' in history? The tenth batch of national procurement pharmaceutical catalog is officially announced, with up to 31 companies competing for a single variety.
①This afternoon, the National Pharmaceutical Centralized Procurement Office officially announced the tenth batch of national procurement pharmaceutical catalog, with a total of 263 specifications and 62 varieties; ②Many industry insiders believe that the tenth batch of national procurement will be the largest and most competitive national procurement in history.
Zheshang Securities: Continuous realization of technological innovation upgrades driving the continuous improvement of performance expectations for innovative drugs and industry chains.
As the innovative drugs industry chain enters the commercialization realization period driven purely by incremental growth, the scarcity of incremental prosperity in the pharmaceutical sector continues to rise, international competitiveness continues to improve, and there is still room for upward valuation.
No Data
No Data